Feng-Ming Spring Kong

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8450719/publications.pdf

Version: 2024-02-01

394	11,343	34105	34986
papers	citations	52 h-index	98 g-index

398	398	398	10015
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Radiation Doseâ€“Volume Effects in the Lung. International Journal of Radiation Oncology Biology Physics, 2010, 76, S70-S76.	0.8	878
2	Nonâ€“Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 740-801.	4.9	606
3	High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable nonâ€“small-cell lung cancer: Long-term results of a radiation dose escalation study. International Journal of Radiation Oncology Biology Physics, 2005, 63, 324-333.	0.8	450
4	Nonâ€“Small Cell Lung Cancer, Version 2.2013. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 645-653.	4.9	357
5	Nonâ€“Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1236-1271.	4.9	312
6	Consideration of Dose Limits for Organs at Risk of Thoracic Radiotherapy: Atlas for Lung, Proximal Bronchial Tree, Esophagus, Spinal Cord, Ribs, and Brachial Plexus. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1442-1457.	0.8	309
7	Final toxicity results of a radiation-dose escalation study in patients with nonâ€“small-cell lung cancer (NSCLC): Predictors for radiation pneumonitis and fibrosis. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1075-1086.	0.8	294
8	Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2017, 35, 1395-1402.	1.6	283
9	Plasma transforming growth factor Î²1 as a predictor of radiation pneumonitis. International Journal of Radiation Oncology Biology Physics, 1998, 41, 1029-1035.	0.8	234
10	Survival Outcome After Stereotactic Body Radiation Therapy and Surgery for Stage I Non-Small Cell Lung Cancer: A Meta-Analysis. International Journal of Radiation Oncology Biology Physics, 2014, 90, 603-611.	0.8	230
11	Physical and biological predictors of changes in whole-lung function following thoracic irradiation. International Journal of Radiation Oncology Biology Physics, 1997, 39, 563-570.	0.8	211
12	Elevated Plasma Transforming Growth Factor-Î²1 Levels in Breast Cancer Patients Decrease After Surgical Removal of the Tumor. Annals of Surgery, 1995, 222, 155-162.	4.2	192
13	18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate?. Journal of Nuclear Medicine, 2006, 47, 1808-12.	5.0	183
14	Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Nonâ€“Small-Cell Lung Cancer. JAMA Oncology, 2017, 3, 1358.	7.1	177
15	Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V30 and transforming growth factor Î². International Journal of Radiation Oncology Biology Physics, 2001, 50, 899-908.	0.8	162
16	Non-Small Cell Lung Cancer Therapy-Related Pulmonary Toxicity: An Update on Radiation Pneumonitis and Fibrosis. Seminars in Oncology, 2005, 32, 42-54.	2.2	158
17	A Pilot Study of [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography Scans During and After Radiation-Based Therapy in Patients With Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2007, 25, 3116-3123.	1.6	154
18	Using Fluorodeoxyglucose Positron Emission Tomography to Assess Tumor Volume During Radiotherapy for Nonâ€“Small-Cell Lung Cancer and Its Potential Impact on Adaptive Dose Escalation and Normal Tissue Sparing. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1228-1234.	0.8	137

#	Article	IF	Citations
19	CT-based definition of thoracic lymph node stations: An atlas from the University of Michigan. International Journal of Radiation Oncology Biology Physics, 2005, 63, 170-178.	0.8	134
20	Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1357-1366.	0.8	134
21	Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis. International Journal of Radiation Oncology Biology Physics, 1997, 37, 253-258.	0.8	130
22	Negative Predictive Value of Positron Emission Tomography and Computed Tomography for Stage T1-2N0 Nonâ€“Small-Cell Lung Cancer: A Meta-Analysis. Clinical Lung Cancer, 2012, 13, 81-89.	2.6	118
23	Nondosimetric Risk Factors for Radiation-Induced Lung Toxicity. Seminars in Radiation Oncology, 2015, 25, 100-109.	2.2	110
24	Review of evolving etiologies, implications and treatment strategies for the superior vena cava syndrome. SpringerPlus, 2016, 5, 229.	1.2	105
25	M6P/IGF2R is mutated in squamous cell carcinoma of the lung. Oncogene, 2000, 19, 1572-1578.	5.9	104
26	Normal tissue complication probability modeling for acute esophagitis in patients treated with conformal radiation therapy for non-small cell lung cancer. Radiotherapy and Oncology, 2005, 77, 176-181.	0.6	101
27	Planning the breast tumor bed boost: Changes in the excision cavity volume and surgical scar location after breast-conserving surgery and whole-breast irradiation. International Journal of Radiation Oncology Biology Physics, 2006, 66, 680-686.	0.8	100
28	The impact of central lung distance, maximal heart distance, and radiation technique on the volumetric dose of the lung and heart for intact breast radiation. International Journal of Radiation Oncology Biology Physics, 2002, 54, 963-971.	0.8	95
29	Radiation produces differential changes in cytokine profiles in radiation lung fibrosis sensitive and resistant mice. Journal of Hematology and Oncology, 2009, 2, 6.	17.0	92
30	Elevation of Plasma TGF-Î²1 During Radiation Therapy Predicts Radiation-Induced Lung Toxicity in Patients With Non-Small-Cell Lung Cancer: A Combined Analysis From Beijing and Michigan. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1385-1390.	0.8	91
31	The predictive role of plasma TGF-Î²1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer. Lung Cancer, 2008, 59, 232-239.	2.0	88
32	Combining Physical and Biologic Parameters to Predict Radiation-Induced Lung Toxicity in Patients With Non-Small-Cell Lung Cancer Treated With Definitive Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2012, 84, e217-e222.	0.8	88
33	Plasma transforming growth factor-Î²1 reflects disease status in patients with lung cancer after radiotherapy: a possible tumor marker. Lung Cancer, 1996, 16, 47-59.	2.0	86
34	Using 18F-Fluorodeoxyglucose Positron Emission Tomography to Estimate the Length of Gross Tumor in Patients With Squamous Cell Carcinoma of the Esophagus. International Journal of Radiation Oncology Biology Physics, 2009, 73, 136-141.	0.8	86
35	The Use of Blood Biomarkers to Predict Radiation Lung Toxicity: A Potential Strategy to Individualize Thoracic Radiation Therapy. Cancer Control, 2008, 15, 140-150.	1.8	84
36	Ultra-high dose rate effect on circulating immune cells: A potential mechanism for FLASH effect?. Radiotherapy and Oncology, 2020, 149, 55-62.	0.6	84

#	Article	IF	Citations
37	Comparison of the Effectiveness of Radiofrequency Ablation With Stereotactic Body Radiation Therapy in Inoperable Stage I Non-Small Cell Lung Cancer: A Systemic Review and Pooled Analysis. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1378-1390.	0.8	83
38	Thymomas and Thymic Carcinomas. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 562-576.	4.9	81
39	Long-term results of high-dose conformal radiotherapy for patients with medically inoperable T1â€“3N0 nonâ€“small-cell lung cancer: Is low incidence of regional failure due to incidental nodal irradiation?. International Journal of Radiation Oncology Biology Physics, 2006, 64, 120-126.	0.8	78
40	Reporting and analyzing statistical uncertainties in Monte Carloâ€“based treatment planning. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1249-1259.	0.8	76
41	Report From the International Atomic Energy Agency (IAEA) Consultants' Meeting on Elective Nodal Irradiation in Lung Cancer: Nonâ€“Small-Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology Biology Physics, 2008, 72, 335-342.	0.8	76
42	Secondary metabolites from Commiphora opobalsamum and their antiproliferative effect on human prostate cancer cells. Phytochemistry, 2007, 68, 1331-1337.	2.9	75
43	Combined Stereotactic Body Radiotherapy and Checkpoint Inhibition in Unresectable Hepatocellular Carcinoma: A Potential Synergistic Treatment Strategy. Frontiers in Oncology, 2019, 9, 1157.	2.8	75
44	Transforming Growth Factor-Beta Receptors and Mannose 6-Phosphate/Insulin-Like Growth Factor-II Receptor Expression in Human Hepatocellular Carcinoma. Annals of Surgery, 1995, 222, 171-178.	4.2	69
45	The Management of Patients With Stage IIIA Nonâ€“Small Cell Lung Cancer With N2 Mediastinal Node Involvement. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 599-613.	4.9	65
46	Normal tissue injury after cancer therapy is a local response exacerbated by an endocrine effect of TGFÎ². British Journal of Radiology, 1995, 68, 331-333.	2.2	63
47	Inhibition of the Tumor Necrosis Factor-Â Pathway Is Radioprotective for the Lung. Clinical Cancer Research, 2008, 14, 1868-1876.	7.0	61
48	The relevance of transforming growth factor Î²1 in pulmonary injury after radiation therapy. Lung Cancer, 1998, 19, 109-120.	2.0	58
49	Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors. Journal of Hematology and Oncology, 2022, 15, .	17.0	58
50	High Radiation Dose May Reduce the Negative Effect of Large Gross Tumor Volume in Patients With Medically Inoperable Early-Stage Nonâ€“Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 68, 103-110.	0.8	57
51	IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients. Cancer Research, 2018, 78, 809-816.	0.9	57
52	Bacterial cell wall polymers promote intestinal fibrosis by direct stimulation of myofibroblasts. American Journal of Physiology - Renal Physiology, 1999, 277, G245-G255.	3.4	54
53	The impact of the effective dose to immune cells on lymphopenia and survival of esophageal cancer after chemoradiotherapy. Radiotherapy and Oncology, 2020, 146, 180-186.	0.6	54
54	A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Nonâ€“Small-Cell Lung Cancer: Results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). Journal of Thoracic Oncology, 2015, 10, 143-147.	1.1	53

#	Article	IF	Citations
55	Physical Models and Simpler Dosimetric Descriptors of Radiation Late Toxicity. Seminars in Radiation Oncology, 2007, 17, 108-120.	2.2	52
56	Report From the International Atomic Energy Agency (IAEA) Consultants' Meeting on Elective Nodal Irradiation in Lung Cancer: Small-Cell Lung Cancer (SCLC). International Journal of Radiation Oncology Biology Physics, 2008, 72, 327-334.	0.8	52
57	Factors associated with overall survival in 1706 patients with nasopharyngeal carcinoma: Significance of intensive neoadjuvant chemotherapy and radiation break. Radiotherapy and Oncology, 2010, 96, 94-99.	0.6	52
58	Organs at Risk Considerations for Thoracic Stereotactic Body Radiation Therapy: What Is Safe for Lung Parenchyma?. International Journal of Radiation Oncology Biology Physics, 2021, 110, 172-187.	0.8	52
59	The Effect of Radiation Dose and Chemotherapy on Overall Survival in 237 Patients With Stage III Nonâ€“Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1383-1390.	0.8	51
60	Penetration of Recommended Procedures for Lung Cancer Staging and Management in the United States Over 10 Years: A Quality Research in Radiation Oncology Survey. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1082-1089.	0.8	51
61	Poor Baseline Pulmonary Function May Not Increase the Risk of Radiation-Induced Lung Toxicity. International Journal of Radiation Oncology Biology Physics, 2013, 85, 798-804.	0.8	50
62	Unraveling biophysical interactions of radiation pneumonitis in non-small-cell lung cancer via Bayesian network analysis. Radiotherapy and Oncology, 2017, 123, 85-92.	0.6	50
63	Plasma Levels of IL-8 and TGF-Î²1 Predict Radiation-Induced Lung Toxicity in Non-Small Cell Lung Cancer: A Validation Study. International Journal of Radiation Oncology Biology Physics, 2017, 98, 615-621.	0.8	48
64	Changes in Global Function and Regional Ventilation and Perfusion on SPECT During the Course of Radiotherapy in Patients With Non-Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, e631-e638.	0.8	46
65	Malignant Pleural Mesothelioma. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 26-41.	4.9	45
66	Higher Radiation Dose to Immune System is Correlated With Poorer Survival in Patients With Stage III Nonâ€“small Cell Lung Cancer: A Secondary Study of a Phase 3 Cooperative Group Trial (NRG Oncology) Tj ETQq0 0 0 rgBT /Overlock 10	0.8	45
67	Tumor control probability modeling for stereotactic body radiation therapy of early-stage lung cancer using multiple bio-physical models. Radiotherapy and Oncology, 2017, 122, 286-294.	0.6	44
68	A multiobjective Bayesian networks approach for joint prediction of tumor local control and radiation pneumonitis in nonsmallâ€cell lung cancer (<scp>NSCLC</scp>) for responseâ€adapted radiotherapy. Medical Physics, 2018, 45, 3980-3995.	3.0	43
69	Effect of Normal Lung Definition on Lung Dosimetry and Lung Toxicity Prediction in Radiation Therapy Treatment Planning. International Journal of Radiation Oncology Biology Physics, 2013, 86, 956-963.	0.8	42
70	Development of a Fully Cross-Validated Bayesian Network Approach for Local Control Prediction in Lung Cancer. IEEE Transactions on Radiation and Plasma Medical Sciences, 2019, 3, 232-241.	3.7	42
71	Radiation dose effect in locally advanced non-small cell lung cancer. Journal of Thoracic Disease, 2014, 6, 336-47.	1.4	41
72	Impact of Fraction Size on Lung Radiation Toxicity: Hypofractionation may be Beneficial in Dose Escalation of Radiotherapy for Lung Cancers. International Journal of Radiation Oncology Biology Physics, 2010, 76, 782-788.	0.8	39

#	Article	IF	Citations
73	Higher Radiation Dose to the Immune Cells Correlates with Worse Tumor Control and Overall Survival in Patients with Stage III NSCLC: A Secondary Analysis of RTOG0617. Cancers, 2021, 13, 6193.	3.7	39
74	Three-dimensional conformal radiation may deliver considerable dose of incidental nodal irradiation in patients with early stage node-negative non-small cell lung cancer when the tumor is large and centrally located. Radiotherapy and Oncology, 2007, 82, 153-159.	0.6	37
75	Semiquantification and Classification of Local Pulmonary Function by V/Q Single Photon Emission Computed Tomography in Patients with Non-small Cell Lung Cancer: Potential Indication for Radiotherapy Planning. Journal of Thoracic Oncology, 2011, 6, 71-78.	1.1	37
76	Noninvasive Evaluation of Microscopic Tumor Extensions Using Standardized Uptake Value and Metabolic Tumor Volume in Non-Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, 960-966.	0.8	36
77	Comparative Survival in Patients With Postresection Recurrent Versus Newly Diagnosed Nonâ€“Small-Cell Lung Cancer Treated With Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 76, 1100-1105.	0.8	35
78	Lymphopenia and Radiation Dose to Circulating Lymphocytes With Neoadjuvant Chemoradiation in Esophageal Squamous Cell Carcinoma. Advances in Radiation Oncology, 2020, 5, 880-888.	1.2	35
79	Circulating thrombomodulin during radiation therapy of lung cancer. Radiation Oncology Investigations, 1999, 7, 238-242.	0.9	33
80	Contouring variations and the role of atlas in non-small cell lung cancer radiation therapy: Analysis of a multi-institutional preclinical trial planning study. Practical Radiation Oncology, 2015, 5, e67-e75.	2.1	33
81	Local Control After Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 110, 160-171.	0.8	32
82	Hyperfractionated accelerated radiation therapy for nonsmall cell lung cancer: Clinical phase trial. International Journal of Radiation Oncology Biology Physics, 1997, 39, 545-552.	0.8	31
83	Plasma Proteomic Analysis May Identify New Markers for Radiation-Induced Lung Toxicity in Patients With Nonâ€“Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 77, 867-876.	0.8	31
84	Survival impact of postoperative therapy modalities according to margin status in nonâ€“small cell lung cancer patients in the United States. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 661-672.e10.	0.8	31
85	Histology, Tumor Volume, and Radiation Dose Predict Outcomes in NSCLC Patients After Stereotactic Ablative Radiotherapy. Journal of Thoracic Oncology, 2018, 13, 1549-1559.	1.1	31
86	Metabolic tumor volume on PET reduced more than gross tumor volume on CT during radiotherapy in patients with non-small cell lung cancer treated with 3DCRT or SBRT. Journal of Radiation Oncology, 2013, 2, 191-202.	0.7	30
87	Transoral Endoscopic Odontoidectomy to Decompress the Cervicomedullary Junction. Spine, 2013, 38, E901-E906.	2.0	30
88	Changes in Functional Lung Regions During the Course of Radiation Therapy and Their Potential Impact on Lung Dosimetry for Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 89, 145-151.	0.8	30
89	Natural growth and disease progression of non-small cell lung cancer evaluated with 18F-fluorodeoxyglucose PET/CT. Lung Cancer, 2012, 78, 51-56.	2.0	29
90	ACR Appropriateness Criteria Nonsurgical Treatment for Nonâ€“Small-Cell Lung Cancer: Poor Performance Status or Palliative Intent. Journal of the American College of Radiology, 2013, 10, 654-664.	1.8	29

#	Article	IF	Citations
91	Chest Wall Toxicity After Stereotactic Body Radiation Therapy: A Pooled Analysis of 57 Studies. International Journal of Radiation Oncology Biology Physics, 2019, 103, 843-850.	0.8	29
92	Doses of radiation to the pericardium, instead of heart, are significant for survival in patients with non-small cell lung cancer. Radiotherapy and Oncology, 2019, 133, 213-219.	0.6	29
93	Quantification of incidental dose to potential clinical target volume (CTV) under different stereotactic body radiation therapy (SBRT) techniques for non-small cell lung cancer â€“ Tumor motion and using internal target volume (ITV) could improve dose distribution in CTV. Radiotherapy and Oncology, 2007, 85, 267-276.	0.6	28
94	Baseline Plasma Proteomic Analysis to Identify Biomarkers that Predict Radiation-Induced Lung Toxicity in Patients Receiving Radiation for Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 1073-1078.	1.1	28
95	Serum MicroRNA Signature Predicts Response to High-Dose Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 100, 107-114.	0.8	28
96	Time to Treatment in Patients With Stage III Nonâ€“Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 74, 790-795.	0.8	27
97	Comparative Proteomic Analysis of Radiation-Induced Changes in Mouse Lung: Fibrosis-Sensitive and -Resistant Strains. Radiation Research, 2008, 169, 417-425.	1.5	26
98	Modern Radiation Further Improves Survival in Non-Small Cell Lung Cancer: An Analysis of 288,670 Patients. Journal of Cancer, 2019, 10, 168-177.	2.5	26
99	A framework for modeling radiation induced lymphopenia in radiotherapy. Radiotherapy and Oncology, 2020, 144, 105-113.	0.6	26
100	Risk factors for symptomatic radiation pneumonitis after stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer. Radiotherapy and Oncology, 2021, 156, 231-238.	0.6	26
101	How Will Big Data Improve Clinical and Basic Research in Radiation Therapy?. International Journal of Radiation Oncology Biology Physics, 2016, 95, 895-904.	0.8	25
102	Circulating microRNAs as biomarkers of radiation-induced cardiac toxicity in non-small-cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1635-1643.	2.5	24
103	A MLC-based inversely optimized 3D spatially fractionated grid radiotherapy technique. Radiotherapy and Oncology, 2015, 117, 483-486.	0.6	23
104	Pretreatment PET/CT imaging of angiogenesis based on 18F-RGD tracer uptake may predict antiangiogenic response. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 940-947.	6.4	23
105	124 Plasma transforming growth factor Î²1 as a predictor of radiation pneumonitis. International Journal of Radiation Oncology Biology Physics, 1997, 39, 197.	0.8	22
106	Pulmonary Artery Invasion, High-Dose Radiation, and Overall Survival in Patients With Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 89, 313-321.	0.8	22
107	Timing and intensity of changes in FDG uptake with symptomatic esophagitis during radiotherapy or chemo-radiotherapy. Radiation Oncology, 2014, 9, 37.	2.7	22
108	Concurrent brain radiotherapy and EGFR-TKI may improve intracranial metastases control in non-small cell lung cancer and have survival benefit in patients with low DS-GPA score. Oncotarget, 2017, 8, 111309-111317.	1.8	22

#	Article	IF	Citations
109	Using Acupressure to Modify Alertness in the Classroom: A Single-Blinded, Randomized, Cross-Over Trial. Journal of Alternative and Complementary Medicine, 2005, 11, 673-679.	2.1	21
110	ACR Appropriateness CriteriaÂ® Noninvasive Clinical Staging of Bronchogenic Carcinoma. Journal of Thoracic Imaging, 2010, 25, W107-W111.	1.5	21
111	The Role of Radiation Therapy in Thoracic Tumors. Hematology/Oncology Clinics of North America, 2006, 20, 363-400.	2.2	20
112	Greater reduction in mid-treatment FDG-PET volume may be associated with worse survival in non-small cell lung cancer. Radiotherapy and Oncology, 2019, 132, 241-249.	0.6	20
113	Genetic Variations in TGFÎ²1, tPA, and ACE and Radiation-Induced Thoracic Toxicities in Patients with Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 208-213.	1.1	19
114	Early Assessment of Treatment Responses During Radiation Therapy for Lung Cancer Using Quantitative Analysis of Daily Computed Tomography. International Journal of Radiation Oncology Biology Physics, 2017, 98, 463-472.	0.8	19
115	Stereotactic body radiotherapy as salvage treatment for recurrence of non-small cell lung cancer after prior surgery or radiotherapy. Translational Lung Cancer Research, 2018, 8, 78-87.	2.8	19
116	A Validation Study on IDO Immune Biomarkers for Survival Prediction in Nonâ€“Small Cell Lung Cancer: Radiation Dose Fractionation Effect in Early-Stage Disease. Clinical Cancer Research, 2020, 26, 282-289.	7.0	19
117	NRG-RTOG 1106/ACRIN 6697: A phase IIR trial of standard versus adaptive (mid-treatment PET-based) chemoradiotherapy for stage III NSCLCâ€"Results and comparison to NRG-RTOG 0617 (non-personalized) Tj ETQq1 1 0.784314 rgBT	1.1	19
118	CT localization of axillary lymph nodes in relation to the humeral head: Significance of arm position for radiation therapy planning. Radiotherapy and Oncology, 2005, 77, 191-193.	0.6	18
119	ACR Appropriateness CriteriaÂ® Early-Stage Nonâ€“Smallâ€“Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 201-207.	1.3	18
120	Anatomic, functional and molecular imaging in lung cancer precision radiation therapy: treatment response assessment and radiation therapy personalization. Translational Lung Cancer Research, 2017, 6, 670-688.	2.8	18
121	Ensuring sample quality for blood biomarker studies in clinical trials: a multicenter international study for plasma and serum sample preparation. Translational Lung Cancer Research, 2017, 6, 625-634.	2.8	18
122	Association of Twice-Daily Radiotherapy With Subsequent Brain Metastases in Adults With Small Cell Lung Cancer. JAMA Network Open, 2019, 2, e190103.	5.9	18
123	Patterns of Treatment and Outcomes for Definitive Therapy of Early Stage Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2017, 104, 1881-1888.	1.3	17
124	A TCP model incorporating setup uncertainty and tumor cell density variation in microscopic extension to guide treatment planning. Medical Physics, 2011, 38, 439-448.	3.0	16
125	Thymic Malignancies*. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 1302-1315.	4.9	16
126	ACR Appropriateness CriteriaÂ® Radiation Therapy for Small-Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 206-213.	1.3	16

#	Article	IF	Citations
127	Patterns of practice in radiation therapy for non-small cell lung cancer among members of the American Society for Radiation Oncology. Practical Radiation Oncology, 2014, 4, e133-e141.	2.1	16
128	Machine Learning to Build and Validate a Model for Radiation Pneumonitis Prediction in Patients with Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2019, 25, 4343-4350.	7.0	16
129	Thoracic radiation-induced pleural effusion and risk factors in patients with lung cancer. Oncotarget, 2017, 8, 97623-97632.	1.8	16
130	Combined Stereotactic Body Radiotherapy and Immunotherapy Versus Transarterial Chemoembolization in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Frontiers in Oncology, 2021, 11, 798832.	2.8	16
131	Transclival cerebrospinal fluid rhinorrhea as the initial presenting symptom of a tiny intradural chordoma. Journal of Clinical Neuroscience, 2010, 17, 1083-1085.	1.5	15
132	Use a survival model to correlate single-nucleotide polymorphisms of DNA repair genes with radiation doseâ€“response in patients with non-small cell lung cancer. Radiotherapy and Oncology, 2015, 117, 77-82.	0.6	15
133	Review of thoracic reirradiation with stereotactic body radiation therapy. Practical Radiation Oncology, 2018, 8, 251-265.	2.1	15
134	Intra and Interfraction Mediastinal Nodal Region Motion: Implications for Internal Target Volume Expansions. Medical Dosimetry, 2009, 34, 133-139.	0.9	14
135	Implementation of hypoxia measurement into lung cancer therapy. Lung Cancer, 2012, 75, 146-150.	2.0	14
136	Radiation-induced lung toxicity in non-small-cell lung cancer: Understanding the interactions of clinical factors and cytokines with the dose-toxicity relationship. Radiotherapy and Oncology, 2017, 125, 66-72.	0.6	14
137	Patterns of Practice in Radiation Dose Prescription and Treatment Planning for Patients With Lung Cancer Among Members of American Society of Therapeutic Radiology and Oncology. International Journal of Radiation Oncology Biology Physics, 2007, 69, S483.	0.8	13
138	ACR Appropriateness CriteriaÂ® on Induction and Adjuvant Therapy for Stage N2 Nonâ€“Small-Cell Lung Cancer: Expert Panel on Radiation Oncologyâ€“Lung. International Journal of Radiation Oncology Biology Physics, 2010, 78, 969-974.	0.8	13
139	Surgical treatment of dumbbell-shaped hypoglossal schwannoma via a pure endoscopic transoral approach. Acta Neurochirurgica, 2012, 154, 267-275.	1.7	13
140	Risk factors for radiation induced lymphopenia in patients with breast cancer receiving adjuvant radiotherapy. Annals of Translational Medicine, 2021, 9, 1288-1288.	1.7	13
141	Prognostic Role of Soluble Programmed Death Ligand 1 in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 774131.	2.8	13
142	ACR Appropriateness CriteriaÂ® on Nonsurgical Treatment for Nonâ€“Small-Cell Lung Cancer: Poor Performance Status or Palliative Intent. Journal of the American College of Radiology, 2009, 6, 85-95.	1.8	12
143	Metabolic response assessment with 18F-FDG PET/CT: inter-method comparison and prognostic significance for patients with non-small cell lung cancer. Journal of Radiation Oncology, 2015, 4, 249-256.	0.7	12
144	Lower Incidence of Esophagitis in the Elderly Undergoing Definitive Radiation Therapy for Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 539-546.	1.1	12

#	Article	IF	Citations
145	Comparison of predictive powers of functional and anatomic dosimetric parameters for radiation-induced lung toxicity in locally advanced non-small cell lung cancer. Radiotherapy and Oncology, 2018, 129, 242-248.	0.6	12
146	NF-Î²B functions as a molecular link between tumor cells and Th1/Tc1 T cells in the tumor microenvironment to exert radiation-mediated tumor suppression. Oncotarget, 2016, 7, 23395-23415.	1.8	12
147	Using FDG-PET to Delineate Gross Tumor and Internal Target Volumes. International Journal of Radiation Oncology Biology Physics, 2005, 63, S400-S401.	0.8	11
148	Principal component analysis identifies patterns of cytokine expression in non-small cell lung cancer patients undergoing definitive radiation therapy. PLoS ONE, 2017, 12, e0183239.	2.5	11
149	In regard to De Jaeger et al.: Significance of plasma transforming growth factor-beta levels in radiotherapy for nonâ€“small-cell lung cancer (INT J RADIAT ONCOL BIOL PHYS 2004;58:1378â€“1387). International Journal of Radiation Oncology Biology Physics, 2005, 61, 1276-1277.	0.8	10
150	ACR Appropriateness CriteriaÂ® Postoperative Adjuvant Therapy in Non-Small Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 537-544.	1.3	10
151	The influence of the blood handling process on the measurement of circulating TGF-Î²1. European Cytokine Network, 2012, 23, 1-6.	2.0	10
152	Personalized dose selection in radiation therapy using statistical models for toxicity and efficacy with dose and biomarkers as covariates. Statistics in Medicine, 2014, 33, 5330-5339.	1.6	10
153	Resection of the Intracavernous Sinus Tumors Using a Purely Endoscopic Endonasal Approach. Journal of Craniofacial Surgery, 2014, 25, 295-302.	0.7	10
154	Priority-driven plan optimization in locally advanced lung patients based on perfusion SPECT imaging. Advances in Radiation Oncology, 2016, 1, 281-289.	1.2	10
155	Can radiotherapy potentiate the effectiveness of immune checkpoint inhibitors in lung cancer?. Future Oncology, 2017, 13, 2503-2505.	2.4	10
156	Blood-based biomarkers for precision medicine in lung cancer: precision radiation therapy. Translational Lung Cancer Research, 2017, 6, 661-669.	2.8	10
157	Utilization of a hybrid finite-element based registration method to quantify heterogeneous tumor response for adaptive treatment for lung cancer patients. Physics in Medicine and Biology, 2018, 63, 065017.	3.0	10
158	Prediction of Radiation Esophagitis in Nonâ€“Small Cell Lung Cancer Using Clinical Factors, Dosimetric Parameters, and Pretreatment Cytokine Levels. Translational Oncology, 2018, 11, 102-108.	3.7	10
159	A model combining age, equivalent uniform dose and IL-8 may predict radiation esophagitis in patients with non-small cell lung cancer. Radiotherapy and Oncology, 2018, 126, 506-510.	0.6	10
160	Impact of effective dose to immune cells (EDIC) on lymphocyte nadir and survival in limited-stage SCLC. Radiotherapy and Oncology, 2021, 162, 26-33.	0.6	10
161	Treatment-Related Death during Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Studies. PLoS ONE, 2016, 11, e0157455.	2.5	10
162	Radiation Induced Lymphopenia Is Associated With the Effective Dose to the Circulating Immune Cells in Breast Cancer. Frontiers in Oncology, 2022, 12, .	2.8	10

#	Article	IF	Citations
163	Personalized Radiation Therapy (PRT) for Lung Cancer. Advances in Experimental Medicine and Biology, 2016, 890, 175-202.	1.6	9
164	What Happens When Proton Meets Randomization: Is There a Future for Proton Therapy?. Journal of Clinical Oncology, 2018, 36, 1777-1779.	1.6	9
165	A Classifier for Improving Early Lung Cancer Diagnosis Incorporating Artificial Intelligence and Liquid Biopsy. Frontiers in Oncology, 2022, 12, 853801.	2.8	9
166	ACR Appropriateness CriteriaÂ® Nonsurgical Treatment for Non-Small-Cell Lung Cancer: Good Performance Status/Definitive Intent. Current Problems in Cancer, 2010, 34, 228-249.	2.0	8
167	Functional liver image guided hepatic therapy (FLIGHT) with hepatobiliary iminodiacetic acid (HIDA) scans. Practical Radiation Oncology, 2018, 8, 429-436.	2.1	8
168	Intermediate Dose-Volume Parameters, Not Low-Dose Bath, Is Superior to Predict Radiation Pneumonitis for Lung Cancer Treated With Intensity-Modulated Radiotherapy. Frontiers in Oncology, 2020, 10, 584756.	2.8	8
169	Central Airway Toxicity After High Dose Radiation: A Combined Analysis of Prospective Clinical Trials for Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 108, 587-596.	0.8	8
170	Pre-radiotherapy lymphocyte count and platelet-to-lymphocyte ratio may improve survival prediction beyond clinical factors in limited stage small cell lung cancer: model development and validation. Translational Lung Cancer Research, 2020, 9, 2315-2327.	2.8	8
171	Utilize target motion to cover clinical target volume (ctv) â€“ a novel and practical treatment planning approach to manage respiratory motion. Radiotherapy and Oncology, 2008, 89, 292-303.	0.6	7
172	Anatomy of the petrous apex as related to the endoscopic endonasal approach. Journal of Clinical Neuroscience, 2012, 19, 1695-1698.	1.5	7
173	Stereotactic body radiotherapy in patients with multiple lung tumors: a focus on lung dosimetric constraints. Expert Review of Anticancer Therapy, 2019, 19, 959-969.	2.4	7
174	Radiation Therapy for Thoracic Malignancies. Hematology/Oncology Clinics of North America, 2020, 34, 109-125.	2.2	7
175	Weighted-Support Vector Machine Learning Classifier of Circulating Cytokine Biomarkers to Predict Radiation-Induced Lung Fibrosis in Non-Small-Cell Lung Cancer Patients. Frontiers in Oncology, 2020, 10, 601979.	2.8	7
176	An improved internal mammary irradiation technique in radiation treatment of locally advanced breast cancers. Journal of Applied Clinical Medical Physics, 2005, 6, 84-93.	1.9	7
177	Early onset of severe lymphopenia during definitive radiotherapy correlates with mean body dose and predicts poor survival in cervical cancer. Cancer Biomarkers, 2022, 34, 149-159.	1.7	7
178	Designing Targets for Elective Nodal Irradiation in Lung Cancer Radiotherapy: A Planning Study. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1397-1403.	0.8	6
179	Fascin expression in skull base chordoma: correlation with tumor recurrence and dura erosion. Medical Oncology, 2012, 29, 2438-2444.	2.5	6
180	Radiation dose-fractionation effects in spinal cord: comparison of animal and human data. Journal of Radiation Oncology, 2015, 4, 225-233.	0.7	6

#	Article	IF	Citations
181	Radiation-induced lung damage in patients treated with stereotactic body radiotherapy after EGFR-TKIs: is there any difference from stereotactic body radiotherapy alone?. Annals of Palliative Medicine, 2021, 10, 2832-2842.	1.2	6
182	Elective Nodal Irradiation (ENI) in Locally Advanced Nonâ€“Small-Cell Lung Cancer (NSCLC): Evidence Versus Opinion?. International Journal of Radiation Oncology Biology Physics, 2009, 74, 322.	0.8	5
183	Modeling Patient-Specific Dose-Function Response for Enhanced Characterization of Personalized Functional Damage. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1265-1275.	0.8	5
184	Individualized Nomogram for Predicting Survival in Patients with Brain Metastases After Stereotactic Radiosurgery Utilizing Driver Gene Mutations and Volumetric Surrogates. Frontiers in Oncology, 2021, 11, 659538.	2.8	5
185	Serum miRNA signature to identify a patientâ€™s resistance to high-dose radiation therapy for unresectable non-small cell lung cancer.. Journal of Clinical Oncology, 2013, 31, 7580-7580.	1.6	5
186	Multiâ€Contrast Fourâ€dimensional Magnetic Resonance Imaging (MCâ€4Dâ€MRI): development and initial evaluation in liver tumor patients. Medical Physics, 2021, 48, 7984.	3.0	5
187	Comparison of clinical outcome between stereotactic body radiotherapy and radiofrequency ablation for unresectable hepatocellular carcinoma. Medicine (United States), 2022, 101, e28545.	1.0	5
188	Transforming Growth Factor Beta: A Plasma Tumor Marker. , 1998, , 417-430.		4
189	Pattern of failure after high-dose thoracic radiation for non-small cell lung cancer: the University of Michigan experience. Journal of Radiation Oncology, 2012, 1, 267-272.	0.7	4
190	The Impact of the CT Dataset Used for Dose Accumulation on Target and Normal Tissue Doses in Adaptive Radiation Therapy for Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 87, S547.	0.8	4
191	Whole body metabolic tumor volume is a prognostic marker in patients with newly diagnosed stage 3B non-small cell lung cancer, confirmed with external validation. European Journal of Hybrid Imaging, 2017, 1, 8.	1.5	4
192	Endoscopic Approach to Remove Intra-extracranial Tumors in Various Skull Base Regions. Chinese Medical Journal, 2017, 130, 2933-2940.	2.3	4
193	An in-silico quality assurance study of contouring target volumes in thoracic tumors within a cooperative group setting. Clinical and Translational Radiation Oncology, 2019, 15, 83-92.	1.7	4
194	Genetic Variations in the Transforming Growth Factor-Î²1 Pathway May Improve Predictive Power for Overall Survival in Non-small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 599719.	2.8	4
195	Chemotherapy is a risk factor of lymphopenia before adjuvant radiotherapy in breast cancer. Cancer Reports, 2021, , e1525.	1.4	4
196	THâ€ABâ€304â€07: A Twoâ€Stage Signatureâ€Based Data Fusion Mechanism to Predict Radiation Pneumonitis in Patients with Nonâ€Smallâ€Cell Lung Cancer (NSCLC). Medical Physics, 2015, 42, 3702-3702.	3.0	4
197	Monte Carlo-based lung cancer treatment planning incorporating PET-defined target volumes. Journal of Applied Clinical Medical Physics, 2005, 6, 65-76.	1.9	4
198	Does radiation increase the risk of immunotherapy related pneumonitis in cancer patients with thorax radiotherapy combined immune checkpoint inhibitors: A meta-analysis.. Journal of Clinical Oncology, 2020, 38, e15099-e15099.	1.6	4

#	Article	IF	Citations
199	P-624 High dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small cell lung cancer: Long-term results of a radiation dose escalation study. Lung Cancer, 2005, 49, S283.	2.0	3
200	2476. International Journal of Radiation Oncology Biology Physics, 2006, 66, S474-S475.	0.8	3
201	FDG-PET/CT during Radiation Therapy to Predict Survival and Guide Individualized Adaptive Dose Escalation in Patients with Nonâ€“small-cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 75, S35-S36.	0.8	3
202	The Importance of Dry Run Credentialing for RTOG 1106/ACRIN 6697: A Trial of Individualized Adaptive Radiation Therapy for Patients with Locally Advanced Non-small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology Biology Physics, 2012, 84, S26-S27.	0.8	3
203	Serum MicroRNA as a Predictive Marker for Radiation Pneumonitis in Patients With Inoperable/Unresectable Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology Biology Physics, 2013, 87, S93.	0.8	3
204	Pros: concurrent chemo-radiotherapy remains the ideal treatment in fit patients with large volume unresectable stage III non-small cell lung cancer. Translational Lung Cancer Research, 2016, 5, 190-194.	2.8	3
205	Optimizing Cardiac Medications in Patients with Locally Advanced Nonâ€“Small Cell Lung Cancer Undergoing Definitive Radiation. International Journal of Radiation Oncology Biology Physics, 2017, 99, E462.	0.8	3
206	Potential future consideration for imaging and blood-based biomarkers for precision medicine in lung cancer. Translational Lung Cancer Research, 2017, 6, 713-715.	2.8	3
207	A novel receptorâ€like kinase involved in fungal pathogen defence in Arabidopsis thaliana. Journal of Phytopathology, 2018, 166, 506-515.	1.0	3
208	Physician Bias in Prophylactic Cranial Irradiation Decision Makingâ€”An Opportunity for a Patient Decision Aid. Clinical Lung Cancer, 2018, 19, 476-483.	2.6	3
209	Predictors of Nodal and Metastatic Failure in Early Stage Nonâ€“small-cell Lung Cancer After Stereotactic Body Radiation Therapy. Clinical Lung Cancer, 2019, 20, 186-193.e3.	2.6	3
210	Kinetics and dosimetric predictors of acute radiation-induced lymphopenia in pancreatic cancer.. Journal of Clinical Oncology, 2018, 36, 300-300.	1.6	3
211	Association between homologous recombination deficiency and tumor mutational burden in lung cancer.. Journal of Clinical Oncology, 2020, 38, e21043-e21043.	1.6	3
212	Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 0, 12, .	2.8	3
213	The role of stereotactic body radiotherapy in hepatocellular carcinoma: guidelines and evidences. Journal of the National Cancer Center, 2022, 2, 171-182.	7.4	3
214	Potential Determinants for Radiation-Induced Lymphopenia in Patients With Breast Cancer Using Interpretable Machine Learning Approach. Frontiers in Immunology, 0, 13, .	4.8	3
215	A Transfer Learning Framework for Deep Learning-Based CT-to-Perfusion Mapping on Lung Cancer Patients. Frontiers in Oncology, 0, 12, .	2.8	3
216	Radiation-Induced Lung Apoptosis is Mediated by TNF-Alpha Action. International Journal of Radiation Oncology Biology Physics, 2005, 63, S83-S84.	0.8	2

#	Article	IF	Citations
217	Radiation Dose is an Independent Predictor for Overall Survival in Patients With Stage III Unresectable Non-small Cell Lung Cancer Treated by Radiation With and Without Chemotherapy. International Journal of Radiation Oncology Biology Physics, 2007, 69, S59.	0.8	2
218	Single Nucleotide Polymorphisms in DNA Repair Genes May Be Associated With Survival in Patients With Non-small Cell Lung Cancer Treated With Definitive Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2012, 84, S69.	0.8	2
219	High Dose to Large Volumes of Pericardium May Be Associated With Radiation-related Pericardial Effusion and Survival in Patients With NSCLC. International Journal of Radiation Oncology Biology Physics, 2012, 84, S592-S593.	0.8	2
220	Oncology Scanâ€"Thoracic Cancers. International Journal of Radiation Oncology Biology Physics, 2013, 85, 571-574.	0.8	2
221	Simple Clinical Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy in Lung Cancer: A Pooled Analysis of 70 Studies. International Journal of Radiation Oncology Biology Physics, 2014, 90, S60.	0.8	2
222	Predicting liver and lung metastasis in esophageal cancer: does the site of primary tumor really matter?. Journal of Thoracic Disease, 2020, 12, 2996-2999.	1.4	2
223	Long-term survival after salvage SBRT for recurrent or secondary non-small cell lung cancer after prior surgery or radiation therapy.. Journal of Clinical Oncology, 2018, 36, 8558-8558.	1.6	2
224	Coexpression patterns of IDO-1, PD-L1 and EGFR in non-small cell lung cancer.. Journal of Clinical Oncology, 2019, 37, e14279-e14279.	1.6	2
225	Patterns of thyroid dysfunctions during treatment with immune checkpoint inhibitors (ICI) in 59 solid cancer patients.. Journal of Clinical Oncology, 2020, 38, e18567-e18567.	1.6	2
226	Prospective trial of functional liver image-guided hepatic therapy (FLIGHT) with hepatobiliary iminodiacetic acid (HIDA) scans and update of institutional experience.. Journal of Clinical Oncology, 2019, 37, 373-373.	1.6	2
227	Why arenâ€™t we getting consistent results for heart dose and mortality during thoracic radiotherapy?. Annals of Translational Medicine, 2020, 8, 1252-1252.	1.7	2
228	Sequential trans-arterial chemoembolization and stereotactic body radiotherapy followed by immunotherapy (START-FIT) for locally advanced hepatocellular carcinoma: A single-arm, phase II trial.. Journal of Clinical Oncology, 2022, 40, 4091-4091.	1.6	2
229	PET Study Demonstrates Radiation Dependent Changes on Tumor Hypoxia and Proliferation during the Course of Radiotherapy in a Lung Cancer Xenograft Model. International Journal of Radiation Oncology Biology Physics, 2008, 72, S30.	0.8	1
230	Is there a Role for [18F]2-Fluoro-2-Deoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT) in Predicting Radiation Pneumonitis. International Journal of Radiation Oncology Biology Physics, 2008, 72, S691.	0.8	1
231	Factors Associated with Patterns of Practice for Elective Nodal Irradiation in Non-small Cell Lung Cancer Patients among US Radiation Oncologists. International Journal of Radiation Oncology Biology Physics, 2009, 75, S129-S130.	0.8	1
232	Imaging During Radiation Therapy Captures Abrupt and Dramatic Changes. Journal of Thoracic Oncology, 2012, 7, 1736-1737.	1.1	1
233	Comparison of the Effectiveness of Radiofrequency Ablation With Stereotactic Body Radiation Therapy in Inoperable Stage I Non-small Cell Lung Cancer: A Systemic Review and Meta-analysis. International Journal of Radiation Oncology Biology Physics, 2012, 84, S611-S612.	0.8	1
234	Quantitative Evaluation of Impact Upon Tumor Control Probability (TCP) From Quality Assurance Criteria for Non-small Cell Lung Cancer From RTOG 1106 Study. International Journal of Radiation Oncology Biology Physics, 2012, 84, S601.	0.8	1

#	Article	IF	Citations
235	Relationship Between Pulmonary Artery Invasion and High-dose Radiation and Overall Survival in Patients With Non-small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 84, S612.	0.8	1
236	Can Use of an Atlas Decrease Contouring Variability in Non-small Cell Lung Cancer Radiation Therapy? Analysis of the RTOG 1106 Preclinical Trial Planning Study. International Journal of Radiation Oncology Biology Physics, 2012, 84, S573.	0.8	1
237	FDG Pulmonary Uptake Changes During and Post-Radiation Therapy Compared to Pretreatment in Predicting Radiation-Induced Lung Toxicity in Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 87, S77.	0.8	1
238	Toward Individualized Fractionation Schedule for Lung Cancer Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 87, S542.	0.8	1
239	Using gEUD to Model Volume Effects for Pneumonitis in Prospective Data From 4 Non-Small Cell Lung Cancer (NSCLC) Dose-Escalation Trials. International Journal of Radiation Oncology Biology Physics, 2013, 87, S45.	0.8	1
240	IT-36 * PHASE 1/2 STUDY OF THE COMBINATION OF INDOXIMOD AND TEMOZOLOMIDE FOR ADULT PATIENTS WITH TEMOZOLOMIDE-REFRACTORY PRIMARY MALIGNANT BRAIN TUMORS. Neuro-Oncology, 2014, 16, v117-v118.	1.2	1
241	A Blood Biomarker Dependent Survival Model for NSCLC Patients Treated With Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 90, S18.	0.8	1
242	Low Baseline Lymphocyte Count May Predict Poorer Overall Survival in Patients With Head and Neck Cancer Treated With Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 90, S573.	0.8	1
243	A Novel Radiation Pneumonitis Predictive Model With MLD and IL-8 for Non-Small Cell Lung Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2015, 93, S153.	0.8	1
244	Combined Stereotactic Body Radiation Therapy and Immunotherapy on 4T1 Triple-Negative Breast Cancer Murine Model. International Journal of Radiation Oncology Biology Physics, 2016, 96, E583.	0.8	1
245	Individualizing Radiation Dose in Locally Advanced Nonâ€“Small Cell Lung Cancer Patients Using Pretreatment Serum MicroRNA Signatures. International Journal of Radiation Oncology Biology Physics, 2017, 98, 222.	0.8	1
246	Hyperfractionated Accelerated Radiation Therapy May Increase Risk for Brain Metastases in Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 98, 244.	0.8	1
247	Patient Selection for Radiotherapy. , 2018, , 337-341.e3.		1
248	NTCP Model for Radiation Pneumonitis after Stereotactic Body Radiation Therapy in Non-Small Cell Lung Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2018, 102, e716-e717.	0.8	1
249	Reply to Z. Liao et al and R. Rengan et al. Journal of Clinical Oncology, 2018, 36, 2005-2006.	1.6	1
250	Changes in Liver Function after Functional Liver Image-Guided Hepatic Therapy (FLIGHT) as Assessed by Hepabobiliary Iminodiacetic Acid Scans. International Journal of Radiation Oncology Biology Physics, 2019, 105, S59.	0.8	1
251	P1.03-17 Function of Antisense LncRNA RP11-539E17.5 and FAM83A-AS1 Up-Regulating FAM83A in Lung Adenocarcinoma Tumorigenesis and Development. Journal of Thoracic Oncology, 2019, 14, S424.	1.1	1
252	OA06.07 Discrimination of Lung Invasive Adenocarcinoma with Micropapillary Pattern Based on CT Radiomics. Journal of Thoracic Oncology, 2019, 14, S222.	1.1	1

#	Article	IF	Citations
253	P2.12-03 Building and Validating a Lymphocyte Nadir Based Model to Predict Survival in Patients with Limited Stage-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, S813.	1.1	1
254	Significance of radiation esophagitis: Conditional survival assessment in patients with non-small cell lung cancer. Journal of the National Cancer Center, 2021, 1, 31-38.	7.4	1
255	SU-E-T-166: Evaluation of Integral Dose in Intensity-Modulated Radiotherapy and Volumetric Modulated Arc Therapy for Head and Neck Cancer Patient. Medical Physics, 2014, 41, 260-261.	3.0	1
256	Mediastinal germ cell tumors and development of secondary leukemia and solid tumors.. Journal of Clinical Oncology, 2016, 34, e16043-e16043.	1.6	1
257	Long-term survival comparison of stereotactic radiotherapy versus surgery for elderly patients with clinical stage T1-T2 non-small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, 8511-8511.	1.6	1
258	Survival in patients with hepatocellular carcinoma (HCC): A report of 1444 patients treated within a multidisciplinary program.. Journal of Clinical Oncology, 2017, 35, e15652-e15652.	1.6	1
259	Stereotactic body radiation therapy to generate comparable survival to surgery in treating hepatocellular carcinoma (HCC): Results of 756 patients.. Journal of Clinical Oncology, 2017, 35, 4080-4080.	1.6	1
260	The effect of thoracic radiation on overall survival and their association with systemic immune therapy in stage IV NSCLC: Findings from the National Cancer Database.. Journal of Clinical Oncology, 2018, 36, 9103-9103.	1.6	1
261	Racial disparities in non-small cell lung cancer, analysis of the Indiana University Cancer Center registry database 2000-2015.. Journal of Clinical Oncology, 2018, 36, e18622-e18622.	1.6	1
262	Deep learning to develop transcriptomic model for survival prediction in TCGA patients with hepatocellular carcinoma.. Journal of Clinical Oncology, 2020, 38, e14057-e14057.	1.6	1
263	Assessment of patient-reported outcomes in patients treated with radiation therapy to brain malignant tumors.. Journal of Clinical Oncology, 2020, 38, e14521-e14521.	1.6	1
264	Thymoma. Medical Radiology, 2008, , 159-170.	0.1	1
265	Real-World Practice of Hypofractionated Radiotherapy in Patients With Invasive Breast Cancer. Frontiers in Oncology, 2022, 12, 811794.	2.8	1
266	Antitumor activity of bintrafusp alfa in previously treated patients with recurrent or metastatic nasopharyngeal cancer (NPC): A single arm, prospective phase II trial.. Journal of Clinical Oncology, 2022, 40, e18029-e18029.	1.6	1
267	26 Increased plasma transforming growth factor beta1 (TGFÎ²1) level in lung cancer patients may be due to the loss of mannose 6-phosphate/insulin like growth factor 2 receptor (). International Journal of Radiation Oncology Biology Physics, 1997, 39, 147.	0.8	0
268	2155 Plasma transforming growth factor beta1 (TGFÎ²1): A monitor for persistence or recurrence of disease in patients with lung cancer. International Journal of Radiation Oncology Biology Physics, 1997, 39, 318.	0.8	0
269	Identification of M6P/IGF2R as a tumor suppressor gene in lung cancer. International Journal of Radiation Oncology Biology Physics, 1998, 42, 229.	0.8	0
270	NTCP modeling for acute esophagitis in patients treated with conformal radiation therapy for non-small cell lung cancer (NSCLC). International Journal of Radiation Oncology Biology Physics, 2004, 60, S525-S525.	0.8	0

#	Article	IF	Citations
271	PD-112 Patterns of local/regional failure after high dose radiation in patients with inoperable/unrestrictable non-small cell lung cancer. Lung Cancer, 2005, 49, S100.	2.0	0
272	161. International Journal of Radiation Oncology Biology Physics, 2006, 66, S91.	0.8	0
273	1041. International Journal of Radiation Oncology Biology Physics, 2006, 66, S153-S154.	0.8	0
274	2494. International Journal of Radiation Oncology Biology Physics, 2006, 66, S485.	0.8	0
275	PATTERNS OF PRACTICE IN LIMITED-STAGE SMALL CELL LUNG CANCER (LS-SCLC) AMONG RADIATION ONCOLOGISTS. Chest, 2007, 132, 589B.	0.8	0
276	PD5-1-5: Radiation-induced elevation in plasma TGF-beta1 during radiation therapy may be predictive of radiation-induced lung toxicity in patients with non-small cell lung cancer: A combined analysis from Beijing and Michigan. Journal of Thoracic Oncology, 2007, 2, S472-S473.	1.1	0
277	PD5-1-4: Differences in pattern of practice in radiation therapy for patients with non-small cell lung cancer between physicians from the United States and Other Countries. Journal of Thoracic Oncology, 2007, 2, S472.	1.1	0
278	Differences in Pattern of Practice in Radiation Therapy for Patients With Non-Small Cell Lung Cancer between Physicians From Canada and the United States. International Journal of Radiation Oncology Biology Physics, 2007, 69, S503.	0.8	0
279	Differences in Pattern of Practice in Radiation Therapy for Patients With Non-Small Cell Lung Cancer (NSCLC) Between Physicians in China and the United States (US). International Journal of Radiation Oncology Biology Physics, 2007, 69, S527.	0.8	0
280	Current Status of Radiation Oncology Community and Growth in Mainland China During Last 10 Years. International Journal of Radiation Oncology Biology Physics, 2007, 69, S183.	0.8	0
281	The Impact of Histologic Subtype and Stage on Survival in Patients with Non-small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 72, S458.	0.8	0
282	The Additional Value of V/Q SPECT over Q SPECT Alone for Pulmonary Function Mapping before, during and after Radiotherapy in Patients with Nonâ€“small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 75, S448.	0.8	0
283	Radiation Dose is Important for Overall Survival in Patients with Inoperable or Unresectable Nonâ€“small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 75, S475.	0.8	0
284	SPECT-based Dose Rearrangement in Normal Lung to Minimize Loss of Function While Maintaining Physical Dose-based Iso-NTCP Limits. International Journal of Radiation Oncology Biology Physics, 2009, 75, S49.	0.8	0
285	Plasma Cytokine Profile during Radiotherapy may Predict Symptomatic Radiation-induced Lung Toxicity in Patients with Nonâ€“small-cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 75, S109.	0.8	0
286	Plasma Proteomic Analysis of Radiation-induced Changes May Help to Identify Patients at Risk for Radiation-induced Lung Toxicity In Non-small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 75, S173-S174.	0.8	0
287	Concurrent Chemoradiotherapy Increases the Risk of Radiation-Induced Pericardial Effusion in Patients with Locally Advanced Non-small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 78, S501.	0.8	0
288	Tumor Volume and Metabolic Activity in Non-small Cell Lung Cancer: Natural History and Change with Treatment. International Journal of Radiation Oncology Biology Physics, 2010, 78, S506-S507.	0.8	0

#	Article	IF	Citations
289	Genetic Variation in TGFÎ²1, tPA and ACE May Predict Radiation-induced Thoracic Toxicity in Patients with Non-small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 78, S35-S36.	0.8	0
290	Report of Quality Research in Radiation Oncology (QRRO) Survey for Lung Cancer Patients Treated in the USA between 2006 and 2007. International Journal of Radiation Oncology Biology Physics, 2010, 78, S36-S37.	0.8	0
291	Re-irradiation May be a Viable Option for Patients with Local Recurrence after a Definitive Course of Radiation Therapy in Non-small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 78, S533.	0.8	0
292	A TCP Model Incorporating Spatial Variation in Tumor Cell Density and Setup Uncertainty to Guide Treatment Planning. International Journal of Radiation Oncology Biology Physics, 2010, 78, S707.	0.8	0
293	An Adaptive Feedback-driven Optimization Strategy to Minimize Radiation Induced Lung Toxicity (RILT) in High Dose Lung Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 78, S116-S117.	0.8	0
294	The Value of Single Nucleotide Polymorphisms in TGFÎ²1, TPA and ACE in Survival Prediction in Patients with Non-small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 78, S199-S200.	0.8	0
295	Predictors of Radiation-Induced Esophagitis in the Treatment of Lung Cancer: An Analysis of Inflammatory Cytokine Levels and Dosimetric Parameters. International Journal of Radiation Oncology Biology Physics, 2010, 78, S200.	0.8	0
296	The Correlation of Pulmonary FDG PET and Perfusion SPECT Imaging During Radiotherapy for Non-small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 78, S203.	0.8	0
297	Co-morbidities Affect Cancer Treatment Strategies And Outcome In Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC): Report Of Quality Research In Radiation Oncology (QRRO) Data For Stage III NSCLC Patients. International Journal of Radiation Oncology Biology Physics, 2011, 81, S575.	0.8	0
298	Inter-method Variability of [18F]FDG PET Metabolic Response Assessment of Non-small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology Biology Physics, 2011, 81, S625.	0.8	0
299	Comparisons of Local Control and Survival of Stereotactic Body Radiation Therapy Versus Surgery for Stage I Non-small Cell Lung Cancer: A Meta-Analysis. International Journal of Radiation Oncology Biology Physics, 2012, 84, S553-S554.	0.8	0
300	Is Recontouring Organs-at-Risk (OAR) for Adaptive Radiation Therapy Plans for Locally Advanced Lung Cancer Necessary? A Preactivation Analysis From Radiation Therapy Oncology Group (RTOG) 1106. International Journal of Radiation Oncology Biology Physics, 2012, 84, S602.	0.8	0
301	A Novel Multifield Grid Treatment Technique Using MLC-based IMRT. International Journal of Radiation Oncology Biology Physics, 2012, 84, S863-S864.	0.8	0
302	Assessing the Predictive Value of Cytokine Levels for Radiation-Induced Esophagitis in Combination With Clinical and Dosimetric Parameters in Patients Treated for Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 87, S535.	0.8	0
303	Total Lesion Glycolysis (TLG) at Baseline FDG-PET/CT May Predict Survival Better than Maximum Standard Uptake Value (SUVmax) in Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology Biology Physics, 2013, 87, S548.	0.8	0
304	Prediction of Late Pulmonary Function Reduction and Radiation-Induced Toxicity During RT Ventilation and Perfusion Imaging in Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology Biology Physics, 2013, 87, S201-S202.	0.8	0
305	Serum MicroRNA Signature Predicts Survival in Patients With Unresectable/Inoperable Non-Small Cell Lung Cancer Treated With Definitive Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 87, S167.	0.8	0
306	Changes in DLCO Instead of FEV1 During Treatment Are Correlated With Posttreatment Reduction in Pulmonary Function and Toxicity After SBRT or 3DCRT for Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 87, S33-S34.	0.8	0

#	Article	IF	Citations
307	A Blood Biomarker Dependent Survival Model for NSCLC Patients Treated With Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 90, S77.	0.8	0
308	Relationship of Dose and TCP for SBRT of Lung Cancer as Analyzed From a Pooled 118 Studies Using a New Radiobiological Model. International Journal of Radiation Oncology Biology Physics, 2014, 90, S189-S190.	0.8	0
309	Neoadjuvant Twice Daily Chemoradiation Therapy for Esophageal Cancer: Treatment Related Mortality and Long-Term Outcomes. International Journal of Radiation Oncology Biology Physics, 2014, 90, S11.	0.8	0
310	Lewis Lung Cancer Tumor Growth Inhibition by Disruption of Transforming Growth Factor Beta (TGF-Î²1) Pathway in Murine Model. International Journal of Radiation Oncology Biology Physics, 2014, 90, S78.	0.8	0
311	Investigation Into a New Quality Assurance Tool for Radiation Therapy Structure Delineation: Atlas-Based Automatic Segmentation (ABAS) of Cardiac Structures for Non-Small Cell Lung Cancer From RTOG 0617. International Journal of Radiation Oncology Biology Physics, 2014, 90, S735.	0.8	0
312	SPECT-CT Ventilation and Perfusion Changes During and 3 Months After Lung SBRT. International Journal of Radiation Oncology Biology Physics, 2015, 93, S86.	0.8	0
313	Baseline Plasma Proteomic Analysis to Identify Glycoproteins for Prediction of Radiation Induced Lung Toxicity in Patients With Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 93, S151-S152.	0.8	0
314	A Novel Radiation Esophagitis Predictive Model With IL-8, Dosimetric and Clinical Factors for Non-Small Cell Lung Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2015, 93, E430.	0.8	0
315	Changes in Circulating Cytokines and Thymic T-Cells After Total Body and Partial-Body (Right) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 2015, 93, E530.	0.8	0
316	Principal Component Analysis of Plasma Cytokine Changes During Hypofractionated SBRT in Patients With Non-Small Cell Lung Cancer: Is There a Difference From Conventionally Fractionated Radiation?. International Journal of Radiation Oncology Biology Physics, 2015, 93, E541.	0.8	0
317	Small Cell Versus Non-Small Cell Lung Cancer: Survival Difference in 1428 Patients From a Single-Institution. International Journal of Radiation Oncology Biology Physics, 2015, 93, E412.	0.8	0
318	The Plasma Concentration of Epidermal Growth Factor Receptor (EGFR) and Overall Survival (OS) in Non-Small Cell Lung Cancer (NSCLC) Patients. International Journal of Radiation Oncology Biology Physics, 2015, 93, E445.	0.8	0
319	No Significant Difference in Overall Survival between Caucasian and African Americans Patient With Prostate Cancer: An Analysis of 1338 Patients From a Single Institution. International Journal of Radiation Oncology Biology Physics, 2015, 93, E244.	0.8	0
320	Rebuttal from Prof. Kong and Dr. Rabatic. Translational Lung Cancer Research, 2016, 5, 198-200.	2.8	0
321	Trends in Utilization of Radiation in the Treatment of Pediatric Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2016, 96, E553.	0.8	0
322	Cytokine Signature During Early Treatment May Predict Midtreatment Positron Emission Tomography/Computed Tomography and Survival in Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 96, E477.	0.8	0
323	Risk Factors for Noncancer Progressionâ€“Associated Death in Patients With Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 96, E487-E488.	0.8	0
324	A Prognostic Model Combining Genetic Variations in the Transforming Growth Factor-Beta1 Pathway and Clinical Factors for Non-Small Cell Lung Cancer After Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 96, E667.	0.8	0

#	Article	IF	Citations
325	Normalized Median Geodesic Distance, a Novel Shape Descriptor, Predicts Survival in Non-Small Cell Lung Cancer After Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 96, S194.	0.8	0
326	Neoadjuvant twice daily chemoradiotherapy for esophageal cancer: Treatment-related mortality and long-term outcomes. Advances in Radiation Oncology, 2017, 2, 308-315.	1.2	0
327	Chest Wall Toxicity After Stereotactic Body Radiation Therapy for NSCLC: A Pooled Analysis of 57 Studies. International Journal of Radiation Oncology Biology Physics, 2017, 99, E457-E458.	0.8	0
328	Predictors of Long-Term Survival Among Locally Advanced Nonâ€“small Cell Lung Cancer Patients Undergoing Definitive Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 99, E441.	0.8	0
329	Investigation of Heterogeneous Tumor Response in Adaptive Radiation Therapy for Patients With Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, E495.	0.8	0
330	Lower Incidence of Radiation Induced Esophagitis in the Elderly: Role of Cytokines. International Journal of Radiation Oncology Biology Physics, 2017, 99, E496-E497.	0.8	0
331	Clinical Dose-Volume Histogram Analysis for Radiation-Induced Proximal Bronchial Tree Toxicity in Patients With Nonâ€“small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, E501.	0.8	0
332	Factors Associated With Survival in Patients With Nonâ€“small Cell Lung Cancer from a Single Institution Study of 3569 Patients. International Journal of Radiation Oncology Biology Physics, 2017, 99, E508-E509.	0.8	0
333	Esophageal Dose, Clinical Factors, and Cytokines: Predicting Radiation-Induced Esophagitis in Nonâ€“small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, E595.	0.8	0
334	Cardiac Events and Definitive Radiation Therapy for Locally Advanced Nonâ€“small Cell Lung Cancer: A Focus on Patients Without Baseline Coronary Artery Disease. International Journal of Radiation Oncology Biology Physics, 2017, 99, S152-S153.	0.8	0
335	Histology Predicts for Failure in Non-small Cell Lung Cancer Patients after Stereotactic Ablative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 99, S240-S241.	0.8	0
336	Influence of Tumor Locations on the Survival of Patients with Esophageal Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2017, 99, E133.	0.8	0
337	Lower Incidence of Esophagitis in the Elderly Undergoing Definitive Radiation Therapy for Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 98, 247-248.	0.8	0
338	OA02.03 Potential Predictors of Pembrolizumab Associated Pneumonitis: A Retrospective Review of the HCRN LUN 14-179 Trial. Journal of Thoracic Oncology, 2017, 12, S1552.	1.1	0
339	Positron Emission Tomography Imaging of Lung Cancer. , 2018, , 219-232.e4.		0
340	Predictors of Nodal And Metastatic Failure in Early Stage Non-Small Cell Lung Cancer after Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, e676.	0.8	0
341	MS12.02 Clinical Data Available. Journal of Thoracic Oncology, 2018, 13, S267.	1.1	0
342	Risk Factors Associated with Lymphocyte Reduction during Radiotherapy in Patients with Limited Stage Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, E550-E551.	0.8	0

#	Article	IF	Citations
343	Interplay of Cardiac and Pulmonary Toxicity: An Analysis of Prospective Trials for Locally Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, E504.	0.8	0
344	Radiation Induced Lymphopenia and Overall Survival in Patients with Limited Stage Small Cell Lung Cancer Receiving Definitive Chemoradiation. International Journal of Radiation Oncology Biology Physics, 2019, 105, E550.	0.8	0
345	The Effect of Thoracic Radiation Therapy on Overall Survival in SCLC: Findings from the National Cancer Database. International Journal of Radiation Oncology Biology Physics, 2019, 105, E549-E550.	0.8	0
346	The Effect of Bladder Volume on RT Dosimetry during Multiple Sessions of Intracavitary Brachytherapy for Cervical Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, E341-E342.	0.8	0
347	A Potential Survival Impact of Blood Immune Cells in Patients with Cervical Carcinoma Treated with Concurrent Chemoradiotherapy. International Journal of Radiation Oncology Biology Physics, 2019, 105, E343.	0.8	0
348	Effective Dose to Lymphocytes Predicts Lymphopenia and May Predict Survival in Patients Treated with CROSS Regimen in Patients with Squamous Cell Carcinoma of Esophagus. International Journal of Radiation Oncology Biology Physics, 2019, 105, E198-E199.	0.8	0
349	Predictors of Failure and Survival in Patients with Hepatocellular Carcinoma Treated with Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 105, E212-E213.	0.8	0
350	P1.14-40 EGFR-TKIs May Sensitize Radiation Lung Damage in Stereotactic Body Radiotherapy Based on Intensity Analyzing. Journal of Thoracic Oncology, 2019, 14, S570.	1.1	0
351	P1.18-15 Dosimetric and Toxicity Benefits of Adaptive IMRT in Patients with Stage III Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, S632.	1.1	0
352	P2.03-05 PHLPP1 Expression Through AKT and ERK Dual Signaling Pathways May Slow Down the Resistance to TKI in EGFR-Mutated Lung Adenocarcinoma. Journal of Thoracic Oncology, 2019, 14, S684.	1.1	0
353	P1.16-24 Detection of Plasma T790M Mutation After the First Generation EGFR-TKI Resistance of Non-Small Cell Lung Cancer in the Real World. Journal of Thoracic Oncology, 2019, 14, S595-S596.	1.1	0
354	EP1.17-35 CBCT Radiomics May Predict Short-Term SBRT Effect in Early Stage Lung Cancer Patients. Journal of Thoracic Oncology, 2019, 14, S1096.	1.1	0
355	JCSE01.17 Modelling the Immunosuppressive Difference of SBRT and CRT by Simulating the Dose to Circulating Lymphocytes in Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, S131.	1.1	0
356	P1.01-90 Update Phase II Results of Early Primary Tumor Stereotactic Body Radiotherapy Combined with First-Line EGFR-TKI in Advanced EGFR Mutated NSCLC. Journal of Thoracic Oncology, 2019, 14, S395-S396.	1.1	0
357	P2.12-08 Surprisingly Promising Tumor Control Rate of S1 Combination with Anlotinib with Refractory Relapsed SCLC Who Failed â‰¥ 2 Lines Chemotherapy. Journal of Thoracic Oncology, 2019, 14, S815.	1.1	0
358	P1.04-69 Modelling the Immunosuppressive Difference of SBRT and CRT by Simulating the Dose to Circulating Lymphocytes in Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, S468.	1.1	0
359	A Case Report of an Early Response to Definitive Chemoradiation for Esophageal Carcinoma Cuniculatum. Case Reports in Oncological Medicine, 2020, 2020, 1-6.	0.3	0
360	Potential determinants of radiation-induced lymphocyte decrease and lymphopenia in breast cancer patients by machine learning approaches.. Journal of Clinical Oncology, 2021, 39, e12567-e12567.	1.6	0

#	Article	IF	Citations
361	Efficacy and pattern failures of early SBRT to primary tumor in advanced EGFR mutation lung cancer (Target-SBRT): A single-arm phase 2 study.. Journal of Clinical Oncology, 2021, 39, e21130-e21130.	1.6	0
362	An investigation on acquired mutations after TKI treatment in Chinese lung cancer patients.. Journal of Clinical Oncology, 2021, 39, e21162-e21162.	1.6	0
363	Association of IDO immune suppression with brain metastasis in non-small cell lung cancer.. Journal of Clinical Oncology, 2021, 39, e21215-e21215.	1.6	0
364	Deep learning survival model on transcriptomes level in patients with non-small cell lung cancer.. Journal of Clinical Oncology, 2021, 39, e20518-e20518.	1.6	0
365	Circulating immune markers predict the therapeutic effect in primary lung cancer.. Journal of Clinical Oncology, 2021, 39, e21203-e21203.	1.6	0
366	Effect of bladder volume on radiation doses to organs at risk and tumor in cervical cancer during imageâ€‘guided adaptive brachytherapy and treatment outcome analysis. Molecular and Clinical Oncology, 2021, 15, 258.	1.0	0
367	TH-E-230A-06: Comparison of Correction and Model Based Dose Algorithms in Lung Cancer Retrospective Dose Recalculation and Treatment Outcome Evaluation. Medical Physics, 2006, 33, 2295-2295.	3.0	0
368	P3-201: Radiation dose is significantly associated with overall survival in patients with stage III non-small cell lung cancer treated with combined radiation and chemotherapy. Journal of Thoracic Oncology, 2007, 2, S766.	1.1	0
369	Combining cytokines of different pathways may improve predictive power for radiation-induced lung toxicity. Journal of Clinical Oncology, 2008, 26, 22177-22177.	1.6	0
370	Combining plasma TGF-Î²1 and lung dosimetric factor to predict radiation-induced lung toxicity in patients with non-small cell lung cancer: A combined analysis from Beijing and Michigan. Journal of Clinical Oncology, 2008, 26, 7548-7548.	1.6	0
371	SU-GG-T-113: Using Probability Density Functions of Respiratory Motion to Model Motion Effects On Dose Distributions and Optimize Treatment Planning for Lung Cancers. Medical Physics, 2008, 35, 2751-2752.	3.0	0
372	Use of increase in esophageal FDG SUV during radiotherapy to predict radiation esophagitis.. Journal of Clinical Oncology, 2010, 28, e17509-e17509.	1.6	0
373	Thymic Tumors. Medical Radiology, 2011, , 309-328.	0.1	0
374	TH-A-BRA-01: Contouring Variations and Their Impact on Dose-Volume Histograms in Non-Small-Cell Lung Cancer Radiotherapy: Analysis of a Multi- Institutional Pre-Clinical Trial Planning Study. Medical Physics, 2012, 39, 3983-3983.	3.0	0
375	SU-E-T-293: A Radiobiological Model Based Approach to Evaluate Brain Radiotherapy Fractionation Regimens. Medical Physics, 2013, 40, 271-271.	3.0	0
376	Combining radiotherapy and immunotherapy in the treatment of advanced cancer: A limited meta-analysis.. Journal of Clinical Oncology, 2014, 32, 3110-3110.	1.6	0
377	TU-A-BRD-01: Outcomes of Hypofractionated Treatments - Initial Results of the WGSBRT. Medical Physics, 2014, 41, 445-446.	3.0	0
378	Treatment-related deaths after concurrent chemoradiotherapy in locally advanced non-small cell lung cancer: A meta-analysis of randomized studies.. Journal of Clinical Oncology, 2014, 32, 7561-7561.	1.6	0

#	Article	IF	Citations
379	SU-F-BRF-11: Dose Rearrangement in High Dose Locally Advanced Lung Patients Based On Perfusion Imaging. Medical Physics, 2014, 41, 401-401.	3.0	0
380	Chemotherapy-related qualitative, quantitative, anatomic and volumetric changes of the major salivary glands during concurrent head and neck therapy.. Journal of Clinical Oncology, 2016, 34, e17522-e17522.	1.6	0
381	Factors associated with secondary malignancy in pediatric Hodgkin's lymphoma.. Journal of Clinical Oncology, 2016, 34, 10538-10538.	1.6	0
382	Renal cell carcinoma: The effect of targeted therapies on clear cell and non-clear cell histologies.. Journal of Clinical Oncology, 2016, 34, e16077-e16077.	1.6	0
383	Impact of health disparities on outcomes: Do black women with inflammatory breast cancer require individualized treatment intensification?. Journal of Clinical Oncology, 2016, 34, e18075-e18075.	1.6	0
384	TU-AB-202-07: A Novel Method for Registration of Mid-Treatment PET/CT Images Under Conditions of Tumor Regression for Patients with Locally Advanced Lung Cancers. Medical Physics, 2016, 43, 3738-3738.	3.0	0
385	Postoperative radiation for tumor control and overall survival in thymic epithelial tumors (TET): A matched-pair analysis.. Journal of Clinical Oncology, 2017, 35, 8572-8572.	1.6	0
386	Paraneoplastic syndrome and survival in thymic epithelial tumors (TET): The Indiana University experience.. Journal of Clinical Oncology, 2017, 35, 8574-8574.	1.6	0
387	Potential risk factors of pneumonitis associated with consolidation pembrolizumab after chemoradiation in unresectable NSCLC patients.. Journal of Clinical Oncology, 2018, 36, 167-167.	1.6	0
388	Effect of radiation dose escalation on outcomes in patients with N2 stage IIIA NSCLC undergoing induction therapy prior to surgical resection.. Journal of Clinical Oncology, 2018, 36, 8513-8513.	1.6	0
389	Depression in women breast cancer patients receiving radiation therapy: A pilot study.. Journal of Clinical Oncology, 2020, 38, e12546-e12546.	1.6	0
390	Changes of plasma GARP-LTGFÎ²1 complex during chemoradiotherapy may predict survival in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, e21042-e21042.	1.6	0
391	Plasma transforming growth factorâ€Îβ1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer, 1999, 86, 1712-1719.	4.1	0
392	Why aren't we getting consistent results for heart dose and mortality during thoracic radiotherapy?. Annals of Translational Medicine, 2020, 8, 1252.	1.7	0
393	Combined 18F-FDG and 11C-acetate positron emission tomography/computed tomography in staging and treatment decision in patients with hepatocellular carcinoma: A cost-effectiveness analysis.. Journal of Clinical Oncology, 2022, 40, e16176-e16176.	1.6	0
394	Real-world frequency of non-small cell lung cancer with ERBB2 exon 20 insertion (Exon20ins) mutations by site of insertion.. Journal of Clinical Oncology, 2022, 40, e15026-e15026.	1.6	0